What is EXUMA Biotech?
Founded in 2015 and headquartered in West Palm Beach, EXUMA Biotech operates as a private corporation dedicated to high-level biotechnology research. The company focuses on the development of advanced therapeutic platforms, positioning itself as a key player in the intersection of molecular biology and clinical application. By maintaining a lean, research-intensive structure, EXUMA Biotech has cultivated a reputation for technical rigor, attracting institutional backing from diverse sectors including specialized life science investors and international financial groups. Its market position is defined by its commitment to addressing complex medical challenges through proprietary scientific discovery.
How much funding has EXUMA Biotech raised?
EXUMA Biotech has raised a total of $97M across 2 funding rounds:
Series A
$37M
Series B
$60M
Series A (2017): $37M with participation from BioAtla, SunTerra Capital, F1 Bioventures, and SINOBIOWAY GROUP
Series B (2021): $60M led by Americo, F1 BioVentures, and MSD Partners
Key Investors in EXUMA Biotech
BioAtla
A San Diego-based biotechnology firm specializing in the development of novel monoclonal antibody and cell-based therapeutics through proprietary Conditionally Active Biologics platforms.
SunTerra Capital
An investment firm headquartered in Shanghai that provides comprehensive M&A financing, investment banking, and strategic consulting services across global capital markets.
Americo
A long-standing insurance and financial services provider based in Kansas City, offering a diverse portfolio of life insurance, annuities, and retirement planning products.
What's next for EXUMA Biotech?
With the successful closure of its latest financing round, EXUMA Biotech is poised to transition from early-stage research into more advanced clinical development phases. The strategic allocation of these funds will likely prioritize the scaling of its internal R&D capabilities and the expansion of its intellectual property portfolio. As the company navigates the complexities of the biotech regulatory environment, the focus will remain on validating its core therapeutic candidates and establishing potential partnerships to facilitate future commercialization. The firm's ability to maintain investor interest through successive funding cycles suggests a robust long-term outlook for its pipeline and overall corporate sustainability.
See full EXUMA Biotech company page
